(ARKG) ARK Genomic Revolution - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US00214Q3020 • Health
ARKG: Genomics, Gene, Editing, DNA, Sequencing, Diagnostics, Therapeutics
The ARK Genomic Revolution ETF, listed on BATS under the ticker ARKG, is an actively managed exchange-traded fund that primarily invests in equity securities of companies involved in the genomics revolution. This investment theme encompasses a broad range of sectors, including healthcare, information technology, materials, energy, and consumer discretionary. By focusing on companies that are driving innovation in genomics, the fund aims to capture the growth potential of this rapidly evolving field. The fund's investment portfolio is composed of both domestic and foreign equity securities, providing exposure to a diverse range of companies that are leading the genomics revolution.
As a non-diversified fund, the ARK Genomic Revolution ETF is able to concentrate its investments in a smaller number of companies that are deemed to have the highest potential for growth and innovation in the genomics space. This approach allows the fund to take a more targeted approach to investing, rather than spreading its assets across a large number of companies. The fund's investment team conducts extensive research and analysis to identify companies that are at the forefront of the genomics revolution, and that have the potential to drive significant growth and innovation in the years to come. With its focus on the genomics revolution, the fund is well-positioned to capture the growth potential of this rapidly evolving field, and to provide investors with exposure to the companies that are shaping the future of healthcare and biotechnology.
The ARK Genomic Revolution ETF is listed on the BATS exchange and is available to investors in the United States. The fund is managed by ARK Investment Management LLC, a firm that is dedicated to providing investors with access to innovative and disruptive technologies. With its focus on the genomics revolution, the fund is part of a broader suite of investment products that are designed to capture the growth potential of emerging technologies and trends. The fund's ticker symbol is ARKG, and its ISIN is US00214Q3020. For more information about the fund, including its investment objectives, strategies, and risks, investors can visit the ARK Investment Management website at http://www.ark-funds.com.
Additional Sources for ARKG ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ARKG ETF Overview
Market Cap in USD | 1,104m |
Category | Health |
TER | 0.75% |
IPO / Inception | 2014-10-31 |
ARKG ETF Ratings
Growth 5y | -42.2% |
Fundamental | - |
Dividend | 11.9% |
Rel. Strength Industry | -133 |
Analysts | - |
Fair Price Momentum | 23.39 USD |
Fair Price DCF | - |
ARKG Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 39.6% |
ARKG Growth Ratios
Growth Correlation 3m | 22% |
Growth Correlation 12m | -54.2% |
Growth Correlation 5y | -79.5% |
CAGR 5y | -4.01% |
CAGR/Mean DD 5y | -0.08 |
Sharpe Ratio 12m | -0.14 |
Alpha | -46.53 |
Beta | 1.46 |
Volatility | 45.62% |
Current Volume | 5618.6k |
Average Volume 20d | 3273.1k |
As of January 23, 2025, the stock is trading at USD 27.12 with a total of 5,618,600 shares traded.
Over the past week, the price has changed by +11.01%, over one month by +13.14%, over three months by +12.67% and over the past year by -9.05%.
Probably not. Based on ValueRay Analyses, ARK Genomic Revolution (BATS:ARKG) is currently (January 2025) not a good stock to buy. It has a ValueRay Growth Rating of -42.22 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARKG as of January 2025 is 23.39. This means that ARKG is currently overvalued and has a potential downside of -13.75%.
ARK Genomic Revolution has no consensus analysts rating.
According to ValueRays Forecast Model, ARKG ARK Genomic Revolution will be worth about 26.4 in January 2026. The stock is currently trading at 27.12. This means that the stock has a potential downside of -2.65%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 26.4 | -2.7% |